Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection — FDA Drug Shortage

To Be Discontinued — Merck Sharp & Dohme LLC

The FDA lists a drug shortage record for Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection (injection) from Merck Sharp & Dohme LLC with status To Be Discontinued. The shortage was first posted on Sep 9, 2026.

Shortage details

Status
To Be Discontinued
Company
Merck Sharp & Dohme LLC
Package NDC
0006-3856-02
Dosage Form
Injection
Presentation
RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02)
Initial Posting
Sep 9, 2026

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.